Developed Countries Lock Up Covid-19 Vaccines Through 2023 morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.
Provided by Dow Jones
By Jared S. Hopkins and Matt Grossman Pfizer Inc. raised this year s sales forecast for its Covid-19 vaccine to about $26 billion, a 73% increase that reflects the shot s growing role in a long-term global vaccination campaign. World-wide demand for Covid-19 vaccines will remain in force for at least several years as people seek to maintain protection as the virus circulates, Pfizer Chief Executive Albert Bourla said Tuesday on an earnings conference call with analysts. Booster shots likely will be needed some time at least six months after being vaccinated, and then annually going forward, Mr. Bourla said.
Provided by Dow Jones
By Jared S. Hopkins and Matt Grossman Pfizer Inc. said it expects its Covid-19 vaccine to generate about $26 billion in sales this year, a major increase from several months ago that reflects the shot s growing role in the global vaccination campaign. The company also said Tuesday it is working on making the two-dose shot easier for vaccinators to administer and store. It has begun studying an updated version of the vaccine for the dangerous Covid-19 variant first identified in South Africa. The Pfizer vaccine is the most-administered of the three Covid-19 vaccines cleared for use in the U.S. and increasingly is available around the world. Pfizer raised its vaccine sales forecast from $15 billion earlier this year as more countries sign supply agreements.
By Jared S. Hopkins Pfizer Inc. and BioNTech SE asked U.S. health regulators to allow their Covid-19 vaccine to be given to adolescents, which could make the shots available to kids in the coming weeks. The companies said Friday that they asked the U.S. Food and Drug Administration to extend their shot s use to children 12 years and older. The companies also said they planned to make similar requests to regulators in other countries. The Pfizer-BioNTech vaccine is currently authorized in the U.S. for people 16 years and older. Shots from Moderna Inc. and Johnson & Johnson are authorized in the U.S. for use in adults 18 years and older.